Entasis Therapeutics
IPO News: Filed S-1/A: Entasis Therapeutics Launches 4.4mm Share IPO with $16.00 - $18.00 Marketing Range
Entasis Therapeutics

Entasis Therapeutics

NASDAQ:  ETTX

Initial Filing Date:  08/17/18

Launch Date:  09/18/18

Price Range:  $16.00 - $18.00

Shares Offered (Pre-Shoe | mm):  4.4

Primary Shares (mm):  4.4

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $75.0

% Secondary:  0.0%

Shares Outstanding (mm):  12.4

Market Value at Midpoint (mm):  $211.1

Offering as % of Market Value:  35.5%

Bookrunner(s):  Credit Suisse | BMO

Co-Manager(s):  SunTrust Robinson Humphrey | Wedbush

Major Holder(s):  AstraZeneca | Clarus Lifesciences | Novo Holdings | Frazier Life Sciences | Pivotal bioVenture Partners Fund | Sofinnova Venture Partners | TPG Biotechnology Partners | Eventide Asset Management

Description:  Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria.

Note:  Emerging Growth Company

 

Reference Link: S-1/A